Pharmacological Inhibition of PI5P4Kα/β Disrupts Cell Energy Metabolism and Selectively Kills P53-null Tumor Cells

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2021 May 18

PMID 34001596

Citations 17

Authors

Song Chen

Caroline Chandra Tjin

Xiang Gao

Yi Xue

Haoyan Jiao

Ruilin Zhang

Mengnan Wu

Zunyu He

Jonathan Ellman

Ya Ha

Affiliations

Soon will be listed here.

Abstract

Most human cancer cells harbor loss-of-function mutations in the p53 tumor suppressor gene. Genetic experiments have shown that phosphatidylinositol 5-phosphate 4-kinase α and β (PI5P4Kα and PI5P4Kβ) are essential for the development of late-onset tumors in mice with germline p53 deletion, but the mechanism underlying this acquired dependence remains unclear. PI5P4K has been previously implicated in metabolic regulation. Here, we show that inhibition of PI5P4Kα/β kinase activity by a potent and selective small-molecule probe disrupts cell energy homeostasis, causing AMPK activation and mTORC1 inhibition in a variety of cell types. Feedback through the S6K/insulin receptor substrate (IRS) loop contributes to insulin hypersensitivity and enhanced PI3K signaling in terminally differentiated myotubes. Most significantly, the energy stress induced by PI5P4Kαβ inhibition is selectively toxic toward p53-null tumor cells. The chemical probe, and the structural basis for its exquisite specificity, provide a promising platform for further development, which may lead to a novel class of diabetes and cancer drugs.

Citing Articles

Anticancer Potential of Azatetracyclic Derivatives: In Vitro Screening and Selective Cytotoxicity of Azide and Monobrominated Compounds.

Moldoveanu C, Mangalagiu I, Zbancioc G, Danac R, Tataringa G, Zbancioc A Molecules. 2025; 30(3).

PMID: 39942805 PMC: 11820345. DOI: 10.3390/molecules30030702.

Hippo and PI5P4K signaling intersect to control the transcriptional activation of YAP.

Palamiuc L, Johnson J, Haratipour Z, Loughran R, Choi W, Arora G Sci Signal. 2024; 17(838):eado6266.

PMID: 38805583 PMC: 11283293. DOI: 10.1126/scisignal.ado6266.

PIP4K2B Protein Regulation by NSD1 in HPV-Negative Head and Neck Squamous Cell Carcinoma.

Topchu I, Bychkov I, Roshchina E, Makhov P, Boumber Y Cancers (Basel). 2024; 16(6).

PMID: 38539515 PMC: 10968846. DOI: 10.3390/cancers16061180.

Lipid kinases PIP5Ks and PIP4Ks: potential drug targets for breast cancer.

Jin Y, Xue J Front Oncol. 2023; 13:1323897.

PMID: 38156113 PMC: 10753794. DOI: 10.3389/fonc.2023.1323897.

Targeting phosphoinositide signaling in cancer: relevant techniques to study lipids and novel avenues for therapeutic intervention.

Llorente A, Loughran R, Emerling B Front Cell Dev Biol. 2023; 11:1297355.

PMID: 37954209 PMC: 10634348. DOI: 10.3389/fcell.2023.1297355.

References

Copps K, White M . Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2. Diabetologia. 2012; 55(10):2565-2582. PMC: 4011499. DOI: 10.1007/s00125-012-2644-8. View

Montagne J, Stewart M, Stocker H, Hafen E, Kozma S, Thomas G . Drosophila S6 kinase: a regulator of cell size. Science. 1999; 285(5436):2126-9. DOI: 10.1126/science.285.5436.2126. View

Jain R, Mathur M, Lan J, Costales A, Atallah G, Ramurthy S . Discovery of Potent and Selective RSK Inhibitors as Biological Probes. J Med Chem. 2015; 58(17):6766-83. DOI: 10.1021/acs.jmedchem.5b00450. View

Paolo G, De Camilli P . Phosphoinositides in cell regulation and membrane dynamics. Nature. 2006; 443(7112):651-7. DOI: 10.1038/nature05185. View

Manz T, Sivakumaren S, Ferguson F, Zhang T, Yasgar A, Seo H . Discovery and Structure-Activity Relationship Study of ()-5-Methylenethiazolidin-4-one Derivatives as Potent and Selective Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors. J Med Chem. 2020; 63(9):4880-4895. PMC: 7292230. DOI: 10.1021/acs.jmedchem.0c00227. View

Sarkes D, Rameh L . A novel HPLC-based approach makes possible the spatial characterization of cellular PtdIns5P and other phosphoinositides. Biochem J. 2010; 428(3):375-84. PMC: 2944655. DOI: 10.1042/BJ20100129. View

Grishin N . Phosphatidylinositol phosphate kinase: a link between protein kinase and glutathione synthase folds. J Mol Biol. 1999; 291(2):239-47. DOI: 10.1006/jmbi.1999.2973. View

Itoh T, Ijuin T, Takenawa T . A novel phosphatidylinositol-5-phosphate 4-kinase (phosphatidylinositol-phosphate kinase IIgamma) is phosphorylated in the endoplasmic reticulum in response to mitogenic signals. J Biol Chem. 1998; 273(32):20292-9. DOI: 10.1074/jbc.273.32.20292. View

Maddocks O, Berkers C, Mason S, Zheng L, Blyth K, Gottlieb E . Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature. 2012; 493(7433):542-6. PMC: 6485472. DOI: 10.1038/nature11743. View

10.

Berridge M, Irvine R . Inositol phosphates and cell signalling. Nature. 1989; 341(6239):197-205. DOI: 10.1038/341197a0. View

11.

Matoba S, Kang J, Patino W, Wragg A, Boehm M, Gavrilova O . p53 regulates mitochondrial respiration. Science. 2006; 312(5780):1650-3. DOI: 10.1126/science.1126863. View

12.

Nagaraj N, Wisniewski J, Geiger T, Cox J, Kircher M, Kelso J . Deep proteome and transcriptome mapping of a human cancer cell line. Mol Syst Biol. 2011; 7:548. PMC: 3261714. DOI: 10.1038/msb.2011.81. View

13.

Laplante M, Sabatini D . mTOR signaling in growth control and disease. Cell. 2012; 149(2):274-93. PMC: 3331679. DOI: 10.1016/j.cell.2012.03.017. View

14.

Kruiswijk F, Labuschagne C, Vousden K . p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nat Rev Mol Cell Biol. 2015; 16(7):393-405. DOI: 10.1038/nrm4007. View

15.

Pavlova N, Thompson C . The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016; 23(1):27-47. PMC: 4715268. DOI: 10.1016/j.cmet.2015.12.006. View

16.

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

17.

Sivakumaren S, Shim H, Zhang T, Ferguson F, Lundquist M, Browne C . Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent Inhibitors. Cell Chem Biol. 2020; 27(5):525-537.e6. PMC: 7286548. DOI: 10.1016/j.chembiol.2020.02.003. View

18.

Fiume R, Stijf-Bultsma Y, Shah Z, Keune W, Jones D, Jude J . PIP4K and the role of nuclear phosphoinositides in tumour suppression. Biochim Biophys Acta. 2015; 1851(6):898-910. DOI: 10.1016/j.bbalip.2015.02.014. View

19.

Sumita K, Lo Y, Takeuchi K, Senda M, Kofuji S, Ikeda Y . The Lipid Kinase PI5P4Kβ Is an Intracellular GTP Sensor for Metabolism and Tumorigenesis. Mol Cell. 2016; 61(2):187-98. PMC: 4747657. DOI: 10.1016/j.molcel.2015.12.011. View

20.

Wang D, Paddock M, Lundquist M, Sun J, Mashadova O, Amadiume S . PIP4Ks Suppress Insulin Signaling through a Catalytic-Independent Mechanism. Cell Rep. 2019; 27(7):1991-2001.e5. PMC: 6619495. DOI: 10.1016/j.celrep.2019.04.070. View